Globally Recognized Multiple Sclerosis Expert, Dr. Lawrence “Larry” Steinman, Joins Trethera Scientific Advisory Board
Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy
Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor
Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors
Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis
ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways
Co-targeting of convergent nucleotide biosynthetic pathways for leukemia eradication
Nucleoside salvage pathway kinases regulate hematopoiesis by linking nucleotide metabolism with replication stress.